Roche's Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma

Roche announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with MabThera® (rituximab) or a MabThera-containing regimen.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news